The FDA and Peptides

If you've been following the peptides for more than a year, you've heard some version of this story: the FDA cracked down on BPC-157 and TB-500 in 2023, and now things might be changing. What that story usually lacks is the regulatory mechanism — how the FDA's classification system actually works, what has concretely changed, what hasn't changed yet, and what's still coming. The details matter for how you interpret what you're reading elsewhere.

Background: How the Compounding Classification System Works

To understand what's happening, you first need to understand what Category 1 and Category 2 actually mean — because they're frequently mischaracterized.

The FDA's compounding pharmacy framework under Section 503A of the Federal Food, Drug, and Cosmetic Act governs what licensed compounding pharmacies can legally prepare for patients under physician prescription. The relevant lists:

The 503A Bulks List — compounds formally approved for use in pharmacy compounding. If a substance is on this list, a licensed compounding pharmacy can prepare it when a physician prescribes it. This is the pathway through which many people accessed BPC-157, TB-500, and other peptides before 2023.

Category 1 — bulk drug substances that have been nominated for the 503A Bulks List and are under active evaluation. The FDA generally exercises enforcement discretion while evaluation is in progress, meaning compounding pharmacies could typically prepare these compounds while the review was pending.

Category 2 — bulk drug substances that the FDA has designated as presenting significant safety concerns, or for which there is insufficient clinical evidence to support compounding. Category 2 is the restricted designation. Compounds in Category 2 cannot be used in compounding under any circumstances while that designation is in effect. This is not a gray zone — it is an active prohibition.

What Happened in 2023: The Category 2 Designations

Between September 2023 and December 2024, the FDA under the Biden administration assigned 19 peptides to Category 2 status, effectively removing them from the compounding pathway. The compounds included BPC-157, TB-500, GHK-Cu (injectable), MOTS-c, Semax, Epitalon, KPV, Emideltide, PEG-MGF, Melanotan II, and others.

The stated rationale: possible immunogenicity risks, peptide-related manufacturing impurities, and insufficient safety data for human administration. The effect: licensed compounding pharmacies that had been legally preparing these compounds for patients under physician prescription were no longer able to do so. Tailor Made Compounding — one of the largest peptide compounding operations in the US — pleaded guilty to federal charges and forfeited $1.79 million in connection with distributing unapproved compounds including BPC-157.

For patients who had been accessing these compounds through the licensed compounding channel — with physician oversight, pharmaceutical-grade manufacturing, and at least nominal quality controls — the 2023 designations pushed that access to unregulated gray-market vendors. That outcome is worth naming explicitly: a policy designed to protect patients from inadequately characterized compounds drove many of them toward suppliers with no quality oversight whatsoever.

What Changed in February 2026: The RFK Jr. Announcement

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. appeared on Episode #2461 of The Joe Rogan Experience and announced that approximately 14 of the 19 restricted peptides would be moved from Category 2 back to Category 1 — restoring the legal compounding pathway. He described himself as a "big fan" of peptides and characterized the 2023 Category 2 designations as illegal, arguing that the FDA can only restrict compounding when there are genuine safety concerns and that these peptides do not present such concerns.

This announcement generated significant excitement in the peptide community and significant confusion about what it actually meant legally. To be precise: a statement on a podcast by an HHS Secretary, however senior, is a policy signal. It is not a rule change. On February 27, 2026, nothing about the legal status of these compounds changed. The PCAC had not reviewed them. The FDA had not published a formal update. Compounding pharmacies could not legally prepare Category 2 peptides the day after Kennedy's announcement any more than the day before.

What the announcement did do: it signaled the direction of regulatory travel clearly enough that the formal administrative mechanism would follow.

What Changed in April 2026: The Formal Action

On April 15, 2026, the FDA published a Federal Register notice announcing two concrete actions:

First: The removal of 12 peptides from Category 2, effective April 22, 2026. The mechanism was administrative: the original nominators of these substances for the Category 2 list voluntarily withdrew their nominations. Under the FDA's process, once a nomination is withdrawn, the FDA no longer has an active safety-concern submission to evaluate, and the substance comes off Category 2 by default. The compounds removed included BPC-157, TB-500, GHK-Cu (injectable), MOTS-c, Semax, Epitalon, KPV, Emideltide, PEG-MGF, and Melanotan II.

Second: The scheduling of Pharmacy Compounding Advisory Committee (PCAC) meetings to formally evaluate whether seven of these compounds should be added to the 503A Bulks List — which would formally authorize their use in compounding under defined conditions. The first meeting is scheduled for July 23–24, 2026 at the FDA White Oak Campus. The formal public docket is FDA-2025-N-6895, and public comments remain open until July 22, 2026 — one day before the hearing.

The July 23 agenda is confirmed to include: BPC-157 (free base and acetate) for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Emideltide for opioid withdrawal and sleep disorders, and Semax for cerebral ischemia and trigeminal neuralgia.

A second PCAC meeting before the end of February 2027 will cover additional compounds including non-injectable GHK-Cu, Cathelicidin LL-37, Dihexa, and PEG-MGF.

What "Removed from Category 2" Does and Doesn't Mean

This is the most important distinction in the entire story, and one that much of the content about this topic is getting wrong.

What it does mean:

• These compounds no longer carry the "significant safety concerns" designation that formed the legal basis for prohibition
• Compounding pharmacies are no longer explicitly prohibited from preparing them solely on the basis of Category 2 status
• The path to formal 503A Bulks List inclusion — which would definitively authorize compounding — is now open and is proceeding through the scheduled PCAC review

What it doesn't mean:

• These compounds are FDA-approved for human therapeutic use. They are not.
• These compounds are on the 503A Bulks List. They are not — not yet.
• Compounding pharmacies have clear, unambiguous legal authorization to prepare them. The situation is more nuanced: Category 2 prohibition has been lifted, but the positive authorization of Bulks List inclusion hasn't yet been granted.
• The PCAC will necessarily recommend inclusion. The committee is independent, will review the evidence, and could recommend against inclusion for some or all compounds. There is precedent for this: during the Biden administration, peptides that were similarly removed from Category 2 through nomination withdrawal came before the PCAC, which recommended against inclusion on the 503A Bulks List.

The current environment is different from that precedent in important ways: many prior FDA staff have departed, the PCAC has significant vacancies that Kennedy could fill before the July meeting, and the administration has publicly signaled support for broader peptide access. But the PCAC review is a genuine scientific evaluation, not a rubber stamp.

The Political Dimension

This regulatory shift is happening in a specific political context that deserves direct acknowledgment, because it shapes how the evidence will be evaluated.

The reclassification is occurring under an HHS Secretary who publicly characterized the prior administration's Category 2 designations as illegal and who described himself as a "big fan" of peptides before any formal administrative process had been completed. Whether you find that encouraging or concerning likely depends on your prior views about this administration's approach to regulatory science. What is factually accurate: the policy direction is clear, the formal process is now moving, and the PCAC — whose composition Kennedy can influence through appointments — will make recommendations that the current administration is predisposed to follow.

For the purposes of this newsletter: the political dimension is context, not a reason to overstate or understate what the science shows. The compounds being reviewed have genuine preclinical evidence behind them. The human trial data is limited for most of them. Whether the regulatory pathway broadens or not, those two facts remain true.

What Happens Next: The Timeline

April 22, 2026: Category 2 removal effective for 12 peptides including BPC-157 and TB-500.

July 22, 2026: Public comment period closes for FDA docket FDA-2025-N-6895.

July 23–24, 2026: PCAC meets to evaluate BPC-157, TB-500, KPV, MOTS-c, Emideltide, and Semax for potential 503A Bulks List inclusion.

Before end of February 2027: Second PCAC meeting for additional compounds including non-injectable GHK-Cu, LL-37, Dihexa, and PEG-MGF.

After PCAC reviews: FDA considers committee recommendations and, if it agrees, formally adds compounds to the 503A Bulks List through rulemaking. This process has no fixed timeline and could take months to years.

What This Means Practically

For people currently using these compounds:

The gray-market research chemical channel that most people have been using is unchanged by these regulatory developments. Research-use-only labeled compounds remain research-use-only labeled compounds. The compounding pharmacy channel — which would restore physician-supervised access with pharmaceutical-grade manufacturing — remains not formally available until the PCAC process completes and compounds are added to the 503A Bulks List.

The most meaningful practical change if the PCAC recommends inclusion and the FDA follows: licensed compounding pharmacies could once again prepare physician-prescribed BPC-157 and TB-500 under quality-controlled conditions, with a physician's oversight rather than through gray-market purchasing. For people who value the safety margin that pharmaceutical-grade manufacturing and medical supervision provide, this would be a meaningful improvement over the current situation.

For people already managing well through the current gray-market channel with independent lab verification: the compounding pathway restoration would provide an alternative, not a mandate.

The Evidence Question Hasn't Changed

One observation worth closing with: none of this regulatory activity changes what the scientific evidence on these compounds actually shows. BPC-157 has extensive and consistent preclinical data across multiple tissue injury models and limited human evidence. TB-500's collagen organization data is among the cleaner pieces of preclinical evidence in the space. The human trial gap that has always existed for these compounds as systemic injectable agents still exists.

Regulatory reclassification doesn't validate the science. It changes the access pathway. Both of those things matter — but they're different things, and keeping them separate is what this newsletter is for.

Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. The regulatory situation described reflects publicly available information as of May 2026 and may change as the PCAC process proceeds. Consult a qualified healthcare provider and, where relevant, legal counsel regarding current compounding regulations in your jurisdiction.